FFP 102

Drug Profile

FFP 102

Alternative Names: FFP102; PG-102; PG102-prototype

Latest Information Update: 30 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PanGenetics BV
  • Developer FF Pharma; PanGenetics BV
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Crohn's disease
  • Discontinued Psoriatic arthritis

Most Recent Events

  • 30 Sep 2015 Clinical development of FFP 102 is ongoing in the Netherlands
  • 11 Jul 2013 FFP 102 is still in phase I/II trials for Crohn's disease in the Netherlands
  • 23 Jan 2013 PG 102 licensed to FF Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top